Jaguar Health, Inc. Stock News

Jaguar Health (NASDAQ: JAGX ) stock is rocketing higher on Tuesday after the pharmaceutical company announced a new license for a chemo mouth treatment. Jaguar Health is looking to treat chemo mouth,

Former meme stock Jaguar Health (NASDAQ: JAGX ) has won the approval of certain measures meant to help maintain its Nasdaq listing. These include an extension to Aug. 13 to regain compliance by gettin

Click here to register for April 1 investor webcast Company plans to file its Earnings Report on April 1, 2024 on Form 10-K for the year ended December 31, 2023 SAN FRANCISCO, CA / ACCESSWIRE / March

SAN FRANCISCO, CA / ACCESSWIRE / January 29, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present in person on January 31, 2

Top line data for Jaguar Health's pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy forthcoming SAN FRANCISCO, CA / ACCESSWIR

Shares of Jaguar Health Inc. JAGX were mauled for a 21.2% loss in morning trading Tuesday, after the drug maker said it has not yet received data supporting the Phase 3 trial of its treatment of diarr

Jaguar Health, Inc. (JAGX) Q3 2023 Earnings Call Transcript

Click here to register for November 14 investor webcast Company plans to file its Earnings Report on November 14, 2023 on Form 10-Q for the quarter ended September 30, 2023 REMINDER: Jaguar to host vi

Individual and institutional investors as well as advisors, analysts, and members of the financial media are invited to attend Jaguar's real-time interactive presentation SAN FRANCISCO, CA / ACCESSWIR

Top line results of this pivotal trial expected before Thanksgiving More than 1 million cancer patients in the US receive chemotherapy or radiation each year, according to the CDC, and cancer patients

Top line results expected in the coming weeks for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea Jaguar is supporting investigator-initiat

Top line results expected late October 2023 for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea Jaguar is supporting investigator-initiated

Filament Health Corp (OTCQB:FLHLF) told investors that its Magdalena Biosciences joint venture (JV) with Jaguar Health has completed an import of coca leaf to Filament's Metro Vancouver research and d

Click here to access webcast replay Top line results expected late October 2023 for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea Jaguar

Napo Pharmaceuticals, a Jaguar family company, reported completion August 17 of last patient last visit for its pivotal Phase 3 OnTarget trial of crofelemer for preventive treatment of cancer therapy-